読み込み中
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on discovering and developing novel, orally administered, small-molecule therapeutics. The company currently markets two key products: Peramivir injection: An intravenous neuraminidase inhibitor, sold under the brand names RAPIVAB, RAPIACTA, and PERAMIFLU, used for the treatment of acute uncomplicated influenza. ORLADEYO: An oral serine protease inhibitor designed to manage hereditary angioedema. BioCryst's development pipeline includes several promising candidates: BCX9930: An oral factor D inhibitor in Phase II clinical trials for complement-mediated diseases. BCX9250: An oral activin receptor-like kinase-2 inhibitor undergoing Phase I clinical evaluation for fibrodysplasia ossificans progressiva. Galidesivir: An RNA dependent-RNA polymerase inhibitor, also in Phase I, aimed at treating a range of RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company engages in strategic collaborations and in-license agreements with numerous partners. These include pharmaceutical entities like Torii Pharmaceutical Co., Ltd., Seqirus UK Limited, Shionogi & Co., Ltd., Green Cross Corporation, and Mundipharma International Holdings Limited. Their alliances also extend to governmental and academic organizations such as the National Institute of Allergy and Infectious Diseases, the Biomedical Advanced Research and Development Authority, the U.S. Department of Health and Human Services, The University of Alabama at Birmingham, Albert Einstein College of Medicine of Yeshiva University, and Industrial Research, Ltd. Established in 1986, BioCryst Pharmaceuticals, Inc. is headquartered in Durham, North Carolina.
前日終値
$8.55
+$0.26 · +3.14%
日中の時刻はETです。市場データは遅延する場合があります。
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on discovering and developing novel, orally administered, small-molecule therapeutics. The company currently markets two key products: Peramivir injection: An intravenous neuraminidase inhibitor, sold under the brand names RAPIVAB, RAPIACTA, and PERAMIFLU, used for the treatment of acute uncomplicated influenza. ORLADEYO: An oral serine protease inhibitor designed to manage hereditary angioedema. BioCryst's development pipeline includes several promising candidates: BCX9930: An oral factor D inhibitor in Phase II clinical trials for complement-mediated diseases. BCX9250: An oral activin receptor-like kinase-2 inhibitor undergoing Phase I clinical evaluation for fibrodysplasia ossificans progressiva. Galidesivir: An RNA dependent-RNA polymerase inhibitor, also in Phase I, aimed at treating a range of RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company engages in strategic collaborations and in-license agreements with numerous partners. These include pharmaceutical entities like Torii Pharmaceutical Co., Ltd., Seqirus UK Limited, Shionogi & Co., Ltd., Green Cross Corporation, and Mundipharma International Holdings Limited. Their alliances also extend to governmental and academic organizations such as the National Institute of Allergy and Infectious Diseases, the Biomedical Advanced Research and Development Authority, the U.S. Department of Health and Human Services, The University of Alabama at Birmingham, Albert Einstein College of Medicine of Yeshiva University, and Industrial Research, Ltd. Established in 1986, BioCryst Pharmaceuticals, Inc. is headquartered in Durham, North Carolina.
日中レンジ
現在 $8.55
52週レンジ
現在 $8.55
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
買い
バリュエーション
82
大幅な割安
センチメント
75
強気
リスク
36
中程度のリスク
モメンタム
67
上昇基調
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on discovering and developing novel, orally administered, small-molecule therapeutics. The company currently markets two key products: Peramivir injection: An intravenous neuraminidase inhibitor, sold under the brand names RAPIVAB, RAPIACTA, and PERAMIFLU, used for the treatment of acute uncomplicated influenza. ORLADEYO: An oral serine protease inhibitor designed to manage hereditary angioedema. BioCryst's development pipeline includes several promising candidates: BCX9930: An oral factor D inhibitor in Phase II clinical trials for complement-mediated diseases. BCX9250: An oral activin receptor-like kinase-2 inhibitor undergoing Phase I clinical evaluation for fibrodysplasia ossificans progressiva. Galidesivir: An RNA dependent-RNA polymerase inhibitor, also in Phase I, aimed at treating a range of RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company engages in strategic collaborations and in-license agreements with numerous partners. These include pharmaceutical entities like Torii Pharmaceutical Co., Ltd., Seqirus UK Limited, Shionogi & Co., Ltd., Green Cross Corporation, and Mundipharma International Holdings Limited. Their alliances also extend to governmental and academic organizations such as the National Institute of Allergy and Infectious Diseases, the Biomedical Advanced Research and Development Authority, the U.S. Department of Health and Human Services, The University of Alabama at Birmingham, Albert Einstein College of Medicine of Yeshiva University, and Industrial Research, Ltd. Established in 1986, BioCryst Pharmaceuticals, Inc. is headquartered in Durham, North Carolina.
日中レンジ
現在 $8.55
52週レンジ
現在 $8.55
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 8.75億 USD | 4.51億 USD | 3.31億 USD | 2.71億 USD | 1.57億 USD |
| 売上原価 | 1907.5万 USD | 1248.5万 USD | 466.1万 USD | 659.4万 USD | 726.4万 USD |
| 粗利益 | 8.56億 USD | 4.38億 USD | 3.27億 USD | 2.64億 USD | 1.5億 USD |
| 研究開発 | 1.66億 USD | 1.75億 USD | 2.17億 USD | 2.53億 USD | 2.09億 USD |
| 販売・一般管理 | 3.49億 USD | 2.66億 USD | 2.14億 USD | 1.59億 USD | 1.19億 USD |
| 営業費用 | 5.15億 USD | 4.41億 USD | 4.3億 USD | 4.13億 USD | 3.28億 USD |
| 受取利息 | 1066.8万 USD | 1474.6万 USD | 1577.7万 USD | 512.7万 USD | 6.2万 USD |
| 支払利息 | 7887.2万 USD | 9851.6万 USD | 1.08億 USD | 9909.2万 USD | 5929.4万 USD |
| 減価償却費と償却費 | 138.9万 USD | 124.6万 USD | 165.5万 USD | 143.7万 USD | 77.7万 USD |
| 営業利益 | 3.41億 USD | −254.3万 USD | −1.04億 USD | −1.48億 USD | −1.78億 USD |
| 純利益 | 2.64億 USD | −8888.1万 USD | −2.27億 USD | −2.47億 USD | −1.84億 USD |
会社概要が更新されました 2026年10月12日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$19.00
上昇余地（122.22%）この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI7848.64万0.00%2.3兆 USD0.03%$381.94+0.63%
State Street SPDR S&P Biotech ETFXBI5789.87万0.59%98.74億 USD0.35%$153.77+3.00%
iShares Russell 2000 ETFIWM4881.43万0.06%787.4億 USD0.19%$278.94+0.49%
Vanguard Morningstar Small-Cap ETFVB2833.77万0.02%1853億 USD0.03%$289.48+0.64%
Vanguard Extended Market ETFVXF2782.35万0.03%954億 USD0.05%$235+0.80%
iShares Russell 2000 Growth ETFIWO1718.05万0.12%139.17億 USD0.24%$356.78+0.94%
Vanguard Morningstar Small-Cap Growth ETFVBK1624.15万0.04%447億 USD0.05%$344.74+1.22%
iShares Biotechnology ETFIBB1409.08万0.13%108.2億 USD0.44%$206.49+3.00%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Morningstar Small-Cap ETFVBVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Morningstar Small-Cap Growth ETFVBKiShares Biotechnology ETFIBBAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
